274 related articles for article (PubMed ID: 35021170)
1. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
AlSahow A; Al-Muhaiteeb A; Nawar H; AlHelal B; AlYousef A; Abdallah E; AbuShall A; Elmekawi S; Meshal B; AlQallaf A; AlRajab H
Med Princ Pract; 2022; 31(2):133-141. PubMed ID: 35021170
[TBL] [Abstract][Full Text] [Related]
2. Rituximab use in adult glomerulopathies and its rationale.
Santos JE; Fiel D; Santos R; Vicente R; Aguiar R; Santos I; Amoedo M; Pires C
J Bras Nefrol; 2020 Mar; 42(1):77-93. PubMed ID: 31904761
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in glomerular diseases: a case series and narrative review.
Duarte I; Oliveira J; Outerelo C; Godinho I; Pereira M; Fernandes P; Jorge S; Gameiro J
J Bras Nefrol; 2022; 44(2):187-195. PubMed ID: 34874051
[TBL] [Abstract][Full Text] [Related]
4. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
Ma X; Fang L; Sheng L; Zhou X; Bai S; Zang X; Wang Y; Li M; Lv Z; Zhong Q; Yang X; Wang Y; Hu Y; Yan D; Shi Y; Chen H; Li J; Tao M; Zhuang S; Wang Y; Liu N
Ren Fail; 2023 Dec; 45(1):2237124. PubMed ID: 37482915
[TBL] [Abstract][Full Text] [Related]
5. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
[TBL] [Abstract][Full Text] [Related]
6. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.
Mariani LH; Bomback AS; Canetta PA; Flessner MF; Helmuth M; Hladunewich MA; Hogan JJ; Kiryluk K; Nachman PH; Nast CC; Rheault MN; Rizk DV; Trachtman H; Wenderfer SE; Bowers C; Hill-Callahan P; Marasa M; Poulton CJ; Revell A; Vento S; Barisoni L; Cattran D; D'Agati V; Jennette JC; Klein JB; Laurin LP; Twombley K; Falk RJ; Gharavi AG; Gillespie BW; Gipson DS; Greenbaum LA; Holzman LB; Kretzler M; Robinson B; Smoyer WE; Guay-Woodford LM;
Am J Kidney Dis; 2019 Feb; 73(2):218-229. PubMed ID: 30420158
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
[TBL] [Abstract][Full Text] [Related]
9. Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study.
Wang CS; Glenn DA; Helmuth M; Smith AR; Bomback AS; Canetta PA; Coppock GM; Khalid M; Tuttle KR; Bou-Matar R; Greenbaum LA; Robinson BM; Holzman LB; Smoyer WE; Rheault MN; Gipson D; Mariani LH;
Am J Kidney Dis; 2024 Jan; 83(1):37-46. PubMed ID: 37657635
[TBL] [Abstract][Full Text] [Related]
10. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
[TBL] [Abstract][Full Text] [Related]
11. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
12. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Rovin BH; Adler SG; Barratt J; Bridoux F; Burdge KA; Chan TM; Cook HT; Fervenza FC; Gibson KL; Glassock RJ; Jayne DRW; Jha V; Liew A; Liu ZH; Mejía-Vilet JM; Nester CM; Radhakrishnan J; Rave EM; Reich HN; Ronco P; Sanders JF; Sethi S; Suzuki Y; Tang SCW; Tesar V; Vivarelli M; Wetzels JFM; Lytvyn L; Craig JC; Tunnicliffe DJ; Howell M; Tonelli MA; Cheung M; Earley A; Floege J
Kidney Int; 2021 Oct; 100(4):753-779. PubMed ID: 34556300
[TBL] [Abstract][Full Text] [Related]
13. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
[TBL] [Abstract][Full Text] [Related]
16. Glomerulonephritis Histopathological Pattern Change.
AlYousef A; AlSahow A; AlHelal B; Alqallaf A; Abdallah E; Abdellatif M; Nawar H; Elmahalawy R
BMC Nephrol; 2020 May; 21(1):186. PubMed ID: 32423387
[TBL] [Abstract][Full Text] [Related]
17. [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
Cagnoli L;
G Ital Nefrol; 2003; 20 Suppl 24():S3-47. PubMed ID: 14666502
[TBL] [Abstract][Full Text] [Related]
18. Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab.
Yoshida S; Hanai S; Nakagomi D; Kobayashi K; Takahashi K; Furuya F
Intern Med; 2021 Jan; 60(1):145-150. PubMed ID: 32830174
[TBL] [Abstract][Full Text] [Related]
19. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
Cravedi P
G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
[TBL] [Abstract][Full Text] [Related]
20. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
